| Peer-Reviewed

The Expression and Prognostic Value of NOX4 in Gastric Cancer

Received: 1 August 2018     Accepted: 22 August 2018     Published: 12 October 2018
Views:       Downloads:
Abstract

Background: Gastric cancer (GC) is one of the most common malignant tumors worldwide which threaten the health of human. A lot of work has been done in tumor pathogenesis in recent years, while modest progress in diagnosis and treatment of gastric cancer have been made. Methods: Multiple databases including The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) were explored to identify the expression pattern of Nicotinamide Adenine Dinucleotide Phosphate Oxidase 4 (NOX4), the main source of reactive oxygen species, in gastric cancer. We also analyzed the correlation between the expression level of NOX4 and gastric cancer patients’ clinical features. The prognostic value of NOX4 was explored in TCGA and K-M Plotter. Last, we utilized TCGA and DAVID databases to uncover the underlying molecular mechanisms of NOX4 with TCGA and DAVID databases. Results: We found that NOX4 was upregulated in tumors compared with adjacent non-tumor tissues and overexpression was correlated with tumor invasion and TNM stage in gastric cancer. Furthermore, NOX4 level could be an independent prognostic marker for GC, unacted on the choice of therapy or HER2 expression. Besides, we investigated the potential mechanisms of NOX4 in gastric cancer. Conclusions: Our findings proved that NOX4 may be a new prognostic factor or therapeutic marker for gastric cancer.

Published in American Journal of Internal Medicine (Volume 6, Issue 6)
DOI 10.11648/j.ajim.20180606.11
Page(s) 144-151
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2018. Published by Science Publishing Group

Keywords

NOX4, Prognostic Values, Gastric Cancer

References
[1] Torre, L. A., et al., Global cancer statistics, 2012. CA Cancer J Clin, 2015. 65(2): p. 87-108.
[2] Torre, L. A., et al., Global Cancer Incidence and Mortality Rates and Trends--An Update. Cancer Epidemiol Biomarkers Prev, 2016. 25(1): p. 16-27.
[3] Shanmugasundaram, K., et al., NOX4 functions as a mitochondrial energetic sensor coupling cancer metabolic reprogramming to drug resistance. Nat Commun, 2017. 8(1): p. 997.
[4] Weyemi, U., et al., NADPH Oxidases NOXs and DUOXs as putative targets for cancer therapy. Anticancer Agents Med Chem, 2013. 13(3): p. 502-14.
[5] Eun, H. S., et al., Gene expression of NOX family members and their clinical significance in hepatocellular carcinoma. Sci Rep, 2017. 7(1): p. 11060.
[6] Ito, K., et al., Inhibition of Nox1 induces apoptosis by attenuating the AKT signaling pathway in oral squamous cell carcinoma cell lines. Oncol Rep, 2016. 36(5): p. 2991-2998.
[7] Vaquero, E. C., et al., Reactive oxygen species produced by NAD(P)H oxidase inhibit apoptosis in pancreatic cancer cells. J Biol Chem, 2004. 279(33): p. 34643-54.
[8] Lin, X. L., et al., Overexpression of NOX4 predicts poor prognosis and promotes tumor progression in human colorectal cancer. Oncotarget, 2017. 8(20): p. 33586-33600.
[9] Liu, Z., et al., Hypoxia Accelerates Aggressiveness of Hepatocellular Carcinoma Cells Involving Oxidative Stress, Epithelial-Mesenchymal Transition and Non-Canonical Hedgehog Signaling. Cell Physiol Biochem, 2017. 44(5): p. 1856-1868.
[10] Thomasz, L., et al., Regulation of NADPH oxidase NOX4 by delta iodolactone (IL-delta) in thyroid cancer cells. Mol Cell Endocrinol, 2017.
[11] Witte, D., et al., TGF-beta1-induced cell migration in pancreatic carcinoma cells is RAC1 and NOX4-dependent and requires RAC1 and NOX4-dependent activation of p38 MAPK. Oncol Rep, 2017. 38(6): p. 3693-3701.
[12] Nitsche, C., et al., The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation. Gastroenterology, 2012. 142(2): p. 377-87 e1-5.
[13] Lee, J., et al., Nanostring-based multigene assay to predict recurrence for gastric cancer patients after surgery. PLoS One, 2014. 9(3): p. e90133.
[14] Gao, X., et al., RNAi-mediated silencing of NOX4 inhibited the invasion of gastric cancer cells through JAK2/STAT3 signaling. Am J Transl Res, 2017. 9(10): p. 4440-4449.
[15] Azouzi, N., et al., NADPH Oxidase NOX4 Is a Critical Mediator of BRAF(V600E)-Induced Downregulation of the Sodium/Iodide Symporter in Papillary Thyroid Carcinomas. Antioxid Redox Signal, 2017. 26(15): p. 864-877.
[16] Auer, S., et al., The Human NADPH Oxidase, Nox4, Regulates Cytoskeletal Organization in Two Cancer Cell Lines, HepG2 and SH-SY5Y. Front Oncol, 2017. 7: p. 111.
[17] Zhang, C., et al., NOX4 promotes non-small cell lung cancer cell proliferation and metastasis through positive feedback regulation of PI3K/Akt signaling. Oncotarget, 2014. 5(12): p. 4392-405.
[18] Govindarajan, B., et al., Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest, 2007. 117(3): p. 719-29.
[19] Edderkaoui, M., et al., NADPH oxidase activation in pancreatic cancer cells is mediated through Akt-dependent up-regulation of p22phox. J Biol Chem, 2013. 288(51): p. 36259.
Cite This Article
  • APA Style

    Lu Qiao, Ning Xie, Yuru Bai, Bin Qin, Baicang Zou, et al. (2018). The Expression and Prognostic Value of NOX4 in Gastric Cancer. American Journal of Internal Medicine, 6(6), 144-151. https://doi.org/10.11648/j.ajim.20180606.11

    Copy | Download

    ACS Style

    Lu Qiao; Ning Xie; Yuru Bai; Bin Qin; Baicang Zou, et al. The Expression and Prognostic Value of NOX4 in Gastric Cancer. Am. J. Intern. Med. 2018, 6(6), 144-151. doi: 10.11648/j.ajim.20180606.11

    Copy | Download

    AMA Style

    Lu Qiao, Ning Xie, Yuru Bai, Bin Qin, Baicang Zou, et al. The Expression and Prognostic Value of NOX4 in Gastric Cancer. Am J Intern Med. 2018;6(6):144-151. doi: 10.11648/j.ajim.20180606.11

    Copy | Download

  • @article{10.11648/j.ajim.20180606.11,
      author = {Lu Qiao and Ning Xie and Yuru Bai and Bin Qin and Baicang Zou and Yongquan Shi and Yan Chen and Na Liu and Jinhai Wang},
      title = {The Expression and Prognostic Value of NOX4 in Gastric Cancer},
      journal = {American Journal of Internal Medicine},
      volume = {6},
      number = {6},
      pages = {144-151},
      doi = {10.11648/j.ajim.20180606.11},
      url = {https://doi.org/10.11648/j.ajim.20180606.11},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20180606.11},
      abstract = {Background: Gastric cancer (GC) is one of the most common malignant tumors worldwide which threaten the health of human. A lot of work has been done in tumor pathogenesis in recent years, while modest progress in diagnosis and treatment of gastric cancer have been made. Methods: Multiple databases including The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) were explored to identify the expression pattern of Nicotinamide Adenine Dinucleotide Phosphate Oxidase 4 (NOX4), the main source of reactive oxygen species, in gastric cancer. We also analyzed the correlation between the expression level of NOX4 and gastric cancer patients’ clinical features. The prognostic value of NOX4 was explored in TCGA and K-M Plotter. Last, we utilized TCGA and DAVID databases to uncover the underlying molecular mechanisms of NOX4 with TCGA and DAVID databases. Results: We found that NOX4 was upregulated in tumors compared with adjacent non-tumor tissues and overexpression was correlated with tumor invasion and TNM stage in gastric cancer. Furthermore, NOX4 level could be an independent prognostic marker for GC, unacted on the choice of therapy or HER2 expression. Besides, we investigated the potential mechanisms of NOX4 in gastric cancer. Conclusions: Our findings proved that NOX4 may be a new prognostic factor or therapeutic marker for gastric cancer.},
     year = {2018}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - The Expression and Prognostic Value of NOX4 in Gastric Cancer
    AU  - Lu Qiao
    AU  - Ning Xie
    AU  - Yuru Bai
    AU  - Bin Qin
    AU  - Baicang Zou
    AU  - Yongquan Shi
    AU  - Yan Chen
    AU  - Na Liu
    AU  - Jinhai Wang
    Y1  - 2018/10/12
    PY  - 2018
    N1  - https://doi.org/10.11648/j.ajim.20180606.11
    DO  - 10.11648/j.ajim.20180606.11
    T2  - American Journal of Internal Medicine
    JF  - American Journal of Internal Medicine
    JO  - American Journal of Internal Medicine
    SP  - 144
    EP  - 151
    PB  - Science Publishing Group
    SN  - 2330-4324
    UR  - https://doi.org/10.11648/j.ajim.20180606.11
    AB  - Background: Gastric cancer (GC) is one of the most common malignant tumors worldwide which threaten the health of human. A lot of work has been done in tumor pathogenesis in recent years, while modest progress in diagnosis and treatment of gastric cancer have been made. Methods: Multiple databases including The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) were explored to identify the expression pattern of Nicotinamide Adenine Dinucleotide Phosphate Oxidase 4 (NOX4), the main source of reactive oxygen species, in gastric cancer. We also analyzed the correlation between the expression level of NOX4 and gastric cancer patients’ clinical features. The prognostic value of NOX4 was explored in TCGA and K-M Plotter. Last, we utilized TCGA and DAVID databases to uncover the underlying molecular mechanisms of NOX4 with TCGA and DAVID databases. Results: We found that NOX4 was upregulated in tumors compared with adjacent non-tumor tissues and overexpression was correlated with tumor invasion and TNM stage in gastric cancer. Furthermore, NOX4 level could be an independent prognostic marker for GC, unacted on the choice of therapy or HER2 expression. Besides, we investigated the potential mechanisms of NOX4 in gastric cancer. Conclusions: Our findings proved that NOX4 may be a new prognostic factor or therapeutic marker for gastric cancer.
    VL  - 6
    IS  - 6
    ER  - 

    Copy | Download

Author Information
  • Department of Gastroenterology, the Second Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China

  • Department of Gastroenterology, the Second Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China

  • Department of Gastroenterology, the Second Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China

  • Department of Gastroenterology, the Second Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China

  • Department of Gastroenterology, the Second Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China

  • Xijing Hospital of Digestive Diseases, Xijing Hospital of the Fourth Military Medical University, Xi'an, China

  • Department of Oncology, Xijing Hospital of the Fourth Military Medical University, Xi'an, China

  • Department of Gastroenterology, the Second Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China

  • Department of Gastroenterology, the Second Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China

  • Sections